Concepedia

Nathanael L. Dirks

NL

Statistics

Publications

6

Citations

553

H-Index

6

Active since

2008

Affiliations

Metrum Research Group (United States)(Current)

Takeda (United States)

University of California San Diego

Takeda (Japan)

Medical University of Vienna

Nathanael L. Dirks is an author at Metrum Research Group (United States) specializing in vedolizumab therapy, pharmacology, and pharmacy.

ORCID

Publications per year

2008–2020

6

Publications

6

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

Maria Rosario, Nathanael L. Dirks, Marc R. Gastonguay et al. · Alimentary Pharmacology & Therapeutics · 2015 · 258 citations · Full text

, , +17

Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease

Maria Rosario, Jonathan French, Nathanael L. Dirks et al. · Journal of Crohn s and Colitis · 2017 · 158 citations · Full text

, , +17

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

Mark T. Osterman, Maria Rosario, Karen Lasch et al. · Alimentary Pharmacology & Therapeutics · 2019 · 88 citations · Full text

, , +17

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease

Hiroyuki Okamoto, Nathanael L. Dirks, Maria Rosario et al. · Intestinal Research · 2020 · 25 citations · Full text

, , +17

P490 A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis

Maria Rosario, Dan Polhamus, C Chen et al. · Journal of Crohn s and Colitis · 2019 · 12 citations · Full text

, , +15

1–5 of 6